DISINTEGRIN VARIANTS AND PHARMACEUTICAL USES THEREOF

Woei-Jer Chuang (Inventor)

Research output: Patent

Abstract

Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.
Original languageEnglish
Patent number60/871,854
Publication statusPublished - 2009 Jul 23

Fingerprint

Disintegrins
Integrins
Pharmaceutical Preparations
Peptides

Cite this

@misc{b0712f4a337240aeb6b6376ca1a1cb76,
title = "DISINTEGRIN VARIANTS AND PHARMACEUTICAL USES THEREOF",
abstract = "Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.",
author = "Woei-Jer Chuang",
year = "2009",
month = "7",
day = "23",
language = "English",
type = "Patent",
note = "60/871,854",

}

TY - PAT

T1 - DISINTEGRIN VARIANTS AND PHARMACEUTICAL USES THEREOF

AU - Chuang, Woei-Jer

PY - 2009/7/23

Y1 - 2009/7/23

N2 - Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.

AB - Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.

M3 - Patent

M1 - 60/871,854

ER -